Life Science Nation (LSN) invites all active family office investors to join the Global Family Office BioForum (GFOB) luncheon, planned during LSN's next conference, RESI Boston June 2025.
The purpose of GFOB is to gather leading family offices who actively invest in life sciences and healthcare sectors to meet, start dialogue, and explore business synergies. This will be a unique opportunity for family offices to foster their network of likeminded individuals with the common goal of advancing therapies and improving quality of care.
- Date: Monday, June 16th
- Time: 12:00 - 1:00 PM
- Location: Westin Copley Place, 10 Huntington Ave, Boston, MA 02116
Please complete the short form below, if you are interested in attending the GFOB luncheon during RESI Boston June 2025.
*You must be an active family office investment firm that makes direct investments into life science and healthcare companies for us to approve your RSVP.
============================================
This year’s GFOB Luncheon features two complementary keynote speakers who will share actionable strategies for how family offices can participate in biotech investing without building internal venture teams or becoming scientific experts.
Chris Garabedian
Founder & CEO, Xontogeny | Portfolio Manager, Perceptive Xontogeny Venture Fund
Chris Garabedian will offer a playbook for how family offices can confidently invest in early-stage therapeutics by partnering with seasoned operators. At Xontogeny, Chris has created a model that pairs hands-on operational support with strategic early capital, guiding startups from idea to clinical inflection points while minimizing founder dilution and maximizing value creation.
Backed by the Perceptive Xontogeny Venture Fund, Xontogeny supports biotech, medtech, and healthtech companies with both funding and execution—giving family offices a way to co-invest alongside industry-proven teams and access a pipeline of high-quality, professionally guided ventures.
Rick Berenson
Executive Committee Member, Mass Medical Angels (MA2)
Rick Berenson will present a practical approach for how family offices can assess early-stage biotech without building a whole internal diligence team. As a 15-year leader at Mass Medical Angels (MA2)—a Boston-based life science group made up entirely of industry veterans—Rick has helped refine a model that quantifies risk and potential return by leveraging the “wisdom of an expert crowd.”
He’ll explain how MA2 has used targeted micro-investments to derisk promising projects and turn them into investable biotech companies and how family offices can take advantage of this model to build a capital-efficient, scalable biotech investment pipeline.